Anavex life sciences announces anavex®2-73 (blarcamesine) meets primary and secondary endpoints in placebo-controlled u.s. phase 2 clinical trial for the treatment of adult patients with rett syndrome

Primary safety, pharmacokinetics and secondary efficacy endpoints met, with consistent improvements in rsbq total scores and cgi-i

AVXL Ratings Summary

AVXL Quant Ranking